Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study

EBioMedicine. 2024 Sep:107:105284. doi: 10.1016/j.ebiom.2024.105284. Epub 2024 Sep 4.

Abstract

Background: The reward-regulatory properties of GLP-1 are attracting increasing interest. Animal studies show that GLP-1 receptor agonists not only reduce consumption of addictive substances, but also influence sexual behaviour. We aimed to investigate the effect of dulaglutide versus placebo on sexual desire in humans.

Methods: In this randomised, double-blind, placebo-controlled crossover trial, healthy eugonadal men of normal weight, aged 18-50 years with active and satisfactory sex lifes were (1:1) randomly allocated to dulaglutide or placebo for four weeks. We assessed sexual desire (Massachusetts General Hospital-Sexual Functioning Questionnaire [MGH-SFQ]), hormones of the hypothalamic-pituitary-gonadal axis (total testosterone, follicle-stimulating hormone [FSH], luteinizing hormone [LH]) and sperm parameters. Changes in these parameters were compared under dulaglutide versus placebo using paired t-tests.

Findings: 24 out of 26 randomised participants completed the study (13 participants randomised to dulaglutide first and 13 to placebo first). No change in the MGH-SFQ was observed after four weeks of dulaglutide versus placebo (estimated difference 0.58 [95% CI -0.83 to 2.00], p-value = 0.402). Hormones of the hypothalamic-pituitary-gonadal axis (estimated differences: total testosterone (nmol/l) 0.9 [95% CI -1.5 to 3.3], FSH (IU/l) -0.2 [95% CI -0.3 to 0.0] and LH (IU/l) -0.8 [95% CI -1.5 to 0.0]) as well as sperm parameters all remained in the normal range without significant differences between the treatments. No severe adverse events occurred.

Interpretation: In this study of healthy men, we found no evidence of negative impacts of a four-week treatment with the widely used GLP-1 receptor agonist dulaglutide on sexual desire, hypothalamic-pituitary-gonadal axis hormones or sperm parameters.

Funding: Swiss National Science Foundation (PZ00P3_193206), Gottfried and Julia Bangerter-Rhyner Foundation, Goldschmidt-Jacobson Foundation, Swiss Academy of Medical Sciences.

Keywords: GLP-1; Hypothalamic-pituitary-gonadal axis; Reward; Sexual desire; Sperm parameters.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Cross-Over Studies*
  • Double-Blind Method
  • Glucagon-Like Peptide-1 Receptor* / agonists
  • Glucagon-Like Peptide-1 Receptor* / metabolism
  • Glucagon-Like Peptides* / analogs & derivatives
  • Glucagon-Like Peptides* / pharmacology
  • Glucagon-Like Peptides* / therapeutic use
  • Humans
  • Immunoglobulin Fc Fragments* / pharmacology
  • Luteinizing Hormone / blood
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins* / pharmacology
  • Testosterone / analogs & derivatives
  • Young Adult

Substances

  • dulaglutide
  • Immunoglobulin Fc Fragments
  • Glucagon-Like Peptides
  • Glucagon-Like Peptide-1 Receptor
  • Recombinant Fusion Proteins
  • Testosterone
  • Luteinizing Hormone